Organ Transplant Immunosuppressant Drugs Market Size to Exceed USD 6.81 Bn by 2032

The Organ Transplant Immunosuppressant Drugs Market, estimated at USD 5.5 Bn in 2025, is expected to exhibit a CAGR of 3.1% and reach USD 6.81 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Immunosuppressive drugs are required to be administered for the rest of the patient’s life after organ transplant to suppress his/her own immune reaction to transplants. Thus, the usage of immunosuppressive drugs is of prime importance to suppress allograft rejection. One of the main factors driving the market growth is the rising transplantation demand as well as the technological developments in tissue engineering and organ transplants.

Global Organ Transplant Immunosuppressant Drugs Market - Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China) in the last months of 2025 as "coronavirus disease 2025" or COVID-19. The virus spread quickly and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

In comparison to pre-pandemic levels, the COVID-19 pandemic has had a major negative impact on the organ transplant immunosuppressant drugs market, with lower demand for transplants across all areas. In comparison to 2025, the global market saw a fall of 52.5% in 2025. The pandemic has also resulted in fewer patients seeing healthcare providers, which has had an additional influence on the volume of organ transplant surgeries carried out. Although there is currently a significant need for organ transplants, technical developments in tissue engineering and organ transplantation are anticipated to fuel the market expansion.

Global Organ Transplant Immunosuppressant Drugss Market: Key Developments

On May 24, 2025, Celltrion USA, a global pharmaceutical company  announced that the U.S. Food and Drug Administration (FDA) approved Yuflyma (adalimumab-aaty), a high-concentration (100mg/mL) and citrate-free formulation of Humira (adalimumab) biosimilar. The FDA granted approval for the treatment of eight conditions: rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa.

In December 2025, Seagen Inc., a global biotechnology company Astellas Pharma Inc., a Japanese multinational pharmaceutical company and Merck, an American multinational pharmaceutical company known as MSD outside of the U.S. and Canada, announced that the U.S. Food and Drug Administration (FDA) has accepted Priority Review supplemental Biologics License Applications (sBLAs) for PADCEV (enfortumab vedotin-ejfv) and KEYTRUDA (pembrolizumab) for the use of these two agents in combination for the treatment of patients with locally advanced or metastatic urothelial cancer (la/mUC) who are not eligible to receive cisplatin-containing chemotherapy.

In July 2025, GSK plc, a U.K. multinational pharmaceutical and biotechnology company, announced that the U.S. Food and Drug Administration (FDA) has approved Benlysta (belimumab) for the treatment of children aged 5 to 17 with active Lupus Nephritis (LN) who are receiving standard therapy.

Browse 32 market data tables and 28 figures spread through 210 Pages and in-depth TOC on “Global Organ Transplant Immunosuppressant Drugs Market, by Drugs Class (Calcineurin Inhibitors, Antiproliferative Agents, mTOR inhibitor, Steroids, and Immunosuppressant Antibodies), by Therapeutic Organ Transplant Type (Heart Transplant, Kidney Transplant, Liver Transplant, Lung Transplant, Pancreas Transplant, and Others), by Distribution Channel (Hospitals, Retail Pharmacies, and Online Pharmacies), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa).

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/organ-transplant-immunosuppressant-drugs-market-2495

Key Takeaways of the Global Organ Transplant Immunosuppressant Drugs Market:

• The global organ transplant immunosuppressant drugs market was valued at US$ 5.5 Bn in 2025 and is forecast to reach a value of US$ 6,3 Bn by 2032 at a CAGR of 3.1% between 2025 and 2032.
• The antibodies segment was valued US$ 1,135.6 Mn in 2025 and is expected to witness a CAGR of 3.7% over the forecast period.
• The key players operating in the global organ transplant immunosuppressant drugs market include Astellas Pharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc., Belcher Pharmaceuticals LLC, Leo Pharma As, Glenmark Pharmaceuticals Ltd., TFF Pharmaceuticals, Inc., TolerogenixX GmbH, Veloxis Pharmaceuticals Inc., Dr. Reddy’s Laboratories Ltd., Panacea Biotec Ltd., Strides Pharma Global Pte Ltd., and Hoffman La Roche